The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed.

1. Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial.PloS one · 2021
   Trial
2. Duffy-null variant and practical implications for patient care: a scoping review.BMJ open · 2025
   Article
3. The DARC-null trait is associated with moderate modulation of NK cell profiles and unaltered cytolytic T cell profiles in black South Africans.PloS one · 2020
   Article
4. CD71mBio · 2019
   Article
5. Neutrophil Effector Functions Are Not Impaired in Duffy Antigen Receptor for Chemokines (DARC)-Null Black South Africans.Frontiers in immunology · 2019
   Article
6. A guide to chemokines and their receptors.The FEBS journal · 2018
   Review
7. Molecular basis of the Duffy blood group system.Blood transfusion = Trasfusione del sangue · 2018
   Review
8. Immune regulation by atypical chemokine receptors.Nature reviews. Immunology · 2013
   Review
9. Platelets and erythrocyte-bound platelets bind infectious HIV-1 in plasma of chronically infected patients.PloS one · 2013
   Article
10. Advances in our understanding of the pathogenesis of HIV-1 associated nephropathy in children.Future virology · 2011
    Article
11. Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2011
    Article
12. Atypical chemokine receptors.Experimental cell research · 2011
    Review
13. DARC and D6: silent partners in chemokine regulation?Immunology and cell biology · 2011
    Review
14. The global distribution of the Duffy blood group.Nature communications · 2011
    Article
15. Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes.Current opinion in HIV and AIDS · 2010
    Review
16. Host genetics and HIV-1: the final phase?PLoS pathogens · 2010
    Review
17. Inference of surface membrane factors of HIV-1 infection through functional interaction networks.PloS one · 2010
    Article
18. A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines.Cellular and molecular life sciences : CMLS · 2010
    Article
19. Host genes associated with HIV/AIDS: advances in gene discovery.Trends in genetics : TIG · 2010
    Review
20. Human erythrocytes selectively bind and enrich infectious HIV-1 virions.PloS one · 2009
    Article

Corrections and comments

• Comment on
  Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility.2008

Authors and funding

16 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as